Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Rad LaboratoriesFRA:BUWA +2.02%75 Net Margin % is 57.05% as of Jun. 2026, which is 427% above its 10-year median of 10.82. GuruFocus rates FRA:BUWA with a GF Score™ of 75/100 and a GF Value™ of €276.51 (Fairly Valued). The stock has 7 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Bio-Rad Laboratories ranks better than 68.67% on this metric.
The historical rank and industry rank for Bio-Rad Laboratories's Net Margin % or its related term are showing as below:
FRA:BUWA'
s Net Margin % Range Over the Past 10 Years
Min: -129.45 Med: 10.82 Max: 149.83
Current: 8.59
FRA:BUWA's Net Margin % is ranked better than 68.67% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs FRA:BUWA: 8.59
Bio-Rad Laboratories (FRA:BUWA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Bio-Rad Laboratories Net Margin % Related Terms
Bio-Rad Laboratories Net Margin % Historical Data
* Premium members only.
The historical data trend for Bio-Rad Laboratories's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BUWA vs GKOS, BRKR, GMED: Net Margin % Comparison
For the Medical Devices subindustry, Bio-Rad Laboratories's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Net Margin % distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories (FRA:BUWA) has a Net Margin % of 57.05% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Bio-Rad Laboratories and its competitors. This is 427% above median its historical median of 10.82. According to the industry distribution chart, Bio-Rad Laboratories ranks #256 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 31.3%.
Is Bio-Rad Laboratories' Net Margin % too high?
Bio-Rad Laboratories' current Net Margin % of 57.05% is 427% above median its 10-year median of 10.82. The Medical Devices & Instruments industry median Net Margin % is 2.05. Bio-Rad Laboratories' value of 57.05% is 2682.9% above this industry median. Based on the distribution chart, Bio-Rad Laboratories ranks #256 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bio-Rad Laboratories has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Net Margin % compare to GKOS and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #256 out of 817 companies for Net Margin %. This puts Bio-Rad Laboratories in the upper half of its industry. The industry median Net Margin % is 2.05. Bio-Rad Laboratories' value of 57.05% is 2682.9% above this benchmark. While the company's 10-year median is 10.82 vs. the industry median of 2.05, Bio-Rad Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.05, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Rad Laboratories's current Net Margin % of 57.05% is 2682.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Bio-Rad Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Rad Laboratories's current Net Margin % is 57.05%, which is 427% above median its own 10-year median of 10.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Fairly Valued. The stock's GF Value™ is €276.51, compared to a current price of €303.00 — trading 9.6% above its estimated fair value. The current Net Margin % is 57.05%, which is 427% above median its 10-year median of 10.82 and 2682.9% above the Medical Devices & Instruments industry median of 2.05. Bio-Rad Laboratories' overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Net Margin % is 57.05% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be overvalued.
The current stock price of €303.00 is trading 9.6% above its estimated GF Value™ of €276.51.
GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.
Key valuation signals for FRA:BUWA:
Net Margin %: 57.05% (427% above median its 10-year median of 10.82)
GF Value™: €276.51 vs. price of €303.00 (9.6% above fair value)
Industry Position: 2682.9% above the Medical Devices & Instruments median (#256 of 817)
No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
75GF Score
Get the complete analysis for FRA:BUWA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BUWA has been successfully added to your 
